Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.34 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA4 | P22748 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5224956 | 0.96 | PARP1 (0.50) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL5224952 | 0.96 | PARP1 (0.50) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL18129846 | 0.96 | PARP1 (0.50) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL4309075 | 0.91 | PARP1 (0.52) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL4312622 | 0.91 | PARP1 (0.52) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL5081566 | 0.91 | PARP1 (0.52) | PARP1ATMMEN1ALDH1A1KMT2A | |
| SCHEMBL30872577 | 0.90 | PARP1 (0.49) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL9052251 | 0.88 | PARP1 (0.50) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL16846248 | 0.88 | PARP1 (0.50) | PARP1ATMCA1CA2CA4 | |
| SCHEMBL19218108 | 0.87 | PARP1 (0.47) | PARP1ATMCA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116867785-A | Compounds and uses thereof | 福宏治疗公司 | 2023-10-10 | — | — | CN | disclosed |
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| CN-1216056-C | Sulfamidohydroxamic acid metalloprotease inhibitor | SEARLE & CO (US) | 2005-08-24 | — | — | CN | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | PARP1 821/4885ATM 3958/4885MEN1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.